bullish

Telix Pharmaceutical US ADS - Past Deal Record Hasn't Been Strong, but Fortune Could Be Turning

477 Views28 May 2024 06:45
Telix Pharmaceuticals (TLX AU) aims to raise at least US$100m in its US ADS listing. The bookrunners on the deal are Jefferies, Morgan Stanley, Truist Securities, and William Blair.
What is covered in the Full Insight:
  • Deal Background
  • Past Funding Deals
  • Recent Performance and Deal Impact
  • Upcoming Developments
  • Analysts' Views and Valuation
Boomeranged on Thu, 6 Jun 2024 14:45
Telix Pharmaceuticals has launched its bookbuild to raise US$200m from its US ADR listing. Pricing is scheduled for 13th Jun 2024, after market close. The shares have continued to trade higher, and are now 15.9% higher than when we first published our note on the deal.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x